| Literature DB >> 32652949 |
Melanie K Schoutteten1,2,3, Julie Vranken4,5, Seulki Lee6, Christophe J P Smeets4,5,6, Hélène De Cannière4,5, Chris Van Hoof7,8, Jacques Peeters4,9, Willemijn Groenendaal6, Pieter M Vandervoort4,5,10.
Abstract
BACKGROUND: Haemodialysis (HD) patients are burdened by frequent fluid shifts which amplify their comorbidities. Bioimpedance (bioZ) is a promising technique to monitor changes in fluid status. The aim of this study is to investigate if the thoracic bioZ signal can track fluid changes during a HD session.Entities:
Keywords: Bioimpedance; Chronic kidney disease; Fluid change; Haemodialysis; Thoracic
Year: 2020 PMID: 32652949 PMCID: PMC7353684 DOI: 10.1186/s12882-020-01922-6
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Ultrafiltration categories
| UF Category | Median UF and IQR (mL) | Number of patientsa | Number of sessions |
|---|---|---|---|
| 600 [300–800] | 8 | 25 | |
| 1500 [1300–1700] | 24 | 51 | |
| 2400 [2000–2500] | 28 | 44 | |
| 3200 [3000–3900] | 8 | 13 |
IQR interquartile range; UF ultrafiltration. aThe number of patients is 68 because two patients were in UF category 2 for one session, and in UF category 1 for another session
Fig. 1Schematic presentation of the wearable device (a) and its attachment to the thorax (b). I current, P bias polar, V voltage
Demographics of the study population
| Demographic variables | Study population ( |
|---|---|
| Gender (male) | 41 (62%) |
| Height (cm) | 166.3 ± 7.9 |
| BMI (kg/m2) | 26.9 ± 4.5 |
| Age (years) | 73 ± 12 |
| Smoking | 17 (26%) |
| Fistula | 27 (41%) |
| Hickmann Catheter | 39 (59%) |
| KT/V | 1.41 ± 0.20 |
| Dialysis vintage (months) | 49.2 ± 46.8 |
| Median UFV (mL) | 1800 [1100–2400] |
| Predialysis SBP/DBP (mmHg) | 134.9 ± 22.1 / 64.3 ± 15.0 |
| Postdialysis SBP/DBP (mmHg) | 129.5 ± 20.3 / 63.5 ± 12.6 |
| Diabetic Kidney Disease | 16 (24%) |
| Non-diabetic Kidney Disease | 53 (80%) |
| Cardiac Diseasea | 39 (59%) |
| Lung Disease (COPD) | 7 (11%) |
| Arterial Hypertension | 47 (71%) |
| Diabetes | 29 (44%) |
| Overweight | 26 (39%) |
| Obesity | 15 (23%) |
aCardiac diseases identified within the study population: cardiomyopathy, systolic dysfunction, ischemic heart failure, decompensated heart failure, heart failure with reduced ejection fraction, coronary artery bypass grafting surgery, aortic valve stenosis and replacement, myocardial infarction, ventricular fibrillation and flutter, the presence of cardiac implantable electronic devices (e.g. pacemaker), atrial fibrillation, bundle branch block, left ventricular hypertrophy
COPD chronic obstructive pulmonary disease; DBP diastolic blood pressure; SBP systolic blood pressure; UFV ultrafiltration volume
Correlation between the relative bioZR values at all frequencies in kHz and UFV. All correlations were statistically significant (p < 0.01). Correlation at 8 kHz was the highest compared to the other frequencies
| UFV | Relative thoracic bioZ | Spearman Correlation |
|---|---|---|
| all categories | 160 | 0.661 |
| 80 | 0.685 | |
| 40 | 0.721 | |
| 26 | 0.728 | |
| 20 | 0.735 | |
| 16 | 0.739 | |
| 13 | 0.747 | |
| 10 | 0.753 | |
bioZ resistance; UFV ultrafiltration volume
Fig. 2Correlation between relative bioZR at 8 kHz and the different UFV categories. All correlations were statistically significant (p < 0.01). Correlation with the higher UFV categories was stronger compared to the smaller volumes.bioZR, resistance; UFV, ultrafiltration volume
Coefficient of determination R2 of the regression model using bioZR, bioZX, and bioZR + X per frequency. R2 is presented as median [25th quartile – 75th quartile]
| Frequency (kHz) | bioZR | bioZX | bioZR + X |
|---|---|---|---|
| 160 | 0.805 [0.545–0.929] | 0.721 [0.294–0.934] | 0.952 [0.848–0.982] |
| 80 | 0.889 [0.665–0.963] | 0.500 [0.123–0.850] | 0.961 [0.888–0.991] |
| 40 | 0.915 [0.717–0.969] | 0.312 [0.065–0.713] | 0.970 [0.888–0.993] |
| 26 | 0.928 [0.752–0.972] | 0.262 [0.077–0.588] | 0.972 [0.884–0.993] |
| 20 | 0.940 [0.768–0.975] | 0.287 [0.096–0.563] | 0.977 [0.893–0.993] |
| 16 | 0.939 [0.798–0.976] | 0.287 [0.102–0.594] | 0.978 [0.918–0.993] |
| 13 | 0.942 [0.790–0.979] | 0.317 [0.105–0.586] | 0.979 [0.922–0.994] |
| 10 | 0.950 [0.787–0.976] | 0.243 [0.117–0.532] | 0.976 [0.903–0.993] |
| 8 | 0.948 [0.801–0.975] | 0.321 [0.116–0.554] | 0.982 [0.912–0.993] |
bioZ resistance; bioZ reactance
Median coefficient of determination Rof the correlation between relative bioZchanges at 8 kHz and UFV according to comorbidities that can influence the thoracic congestion
| Comorbidity | Median R2 |
|---|---|
| no COPD and no heart failurea ( | 0.981 [0.859–0.935] |
| COPD or heart failure ( | 0.982 [0.935–0.994] |
| heart failure ( | 0.979 [0.887–0.992] |
| no heart failure ( | 0.982 [0.914–0.993] |
| COPD ( | 0.988 [0.973–0.997] |
| no COPD ( | 0.980 [0.858–0.993] |
bioZ resistance; bioZ reactance; COPD chronic obstructive pulmonary disease
a Heart failure includes: dilated cardiomyopathy, systolic dysfunction, diastolic dysfunction, left or right sided heart failure
Fig. 3Predicted fluid extraction based on bioZR + X values at 8 kHz and recorded UFV for one session. bioZR + X, resistance and reactance; UFV, ultrafiltration volume